Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346255 · ClinicalTrials.gov registry record · Phase 1
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00346255 is a Phase 1 study that has completed, run by ImmunoGen. The registered enrollment target is 37 participants.
The verdict
NCT00346255, a Phase 1 study, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed and/or refractory multiple myeloma.
Interventions
- DRUG BB-10901
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346255
The ClinicalTrials.gov registry entry for NCT00346255 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BB-10901 is the first listed.
NCT00346255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346255 about?
NCT00346255 is a clinical study titled "BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma". RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase I trial is studying the side effects ...
What is the current status of trial NCT00346255?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2005-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00346255?
The interventions under investigation include: BB-10901 (DRUG).
Who is sponsoring clinical trial NCT00346255?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.